Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Vigil Neuroscience in a research note issued on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.48) per share for the quarter, up from their previous estimate of ($0.58). HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience's Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $0.58 EPS.
Other analysts have also recently issued reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $13.00 price target on shares of Vigil Neuroscience in a research note on Monday, May 5th. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, William Blair raised Vigil Neuroscience to a "strong-buy" rating in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $16.25.
Check Out Our Latest Report on VIGL
Vigil Neuroscience Trading Up 0.4%
Shares of NASDAQ:VIGL opened at $2.42 on Monday. The stock has a market capitalization of $112.95 million, a P/E ratio of -1.17 and a beta of 1.90. The business has a 50-day moving average price of $1.93 and a two-hundred day moving average price of $2.30. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $6.06.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04.
Hedge Funds Weigh In On Vigil Neuroscience
Several institutional investors and hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC grew its position in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares during the period. Northern Trust Corp grew its position in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares during the period. Barclays PLC grew its position in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the period. Two Sigma Investments LP grew its position in shares of Vigil Neuroscience by 44.0% in the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company's stock valued at $233,000 after purchasing an additional 41,836 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Vigil Neuroscience in the 4th quarter valued at approximately $83,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.
Vigil Neuroscience Company Profile
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
